TIPRANIVIR CAPSULE ON CYP450 AND P-GLYCOPROTEIN IN HEALTHY HUMANS

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 替拉那韦是一种新上市的HIV蛋白酶抑制剂，必须与利托那韦一起使用。 许多个体药物相互作用研究已经证明了其高相互作用潜力。 其中一些相互作用研究（特别是与其他蛋白酶抑制剂的相互作用研究）的结果令人惊讶，并且未基于这些相互作用进行预测，并且将允许进一步探索潜在重要药物相互作用的一般信号。 选择健康的男性和女性志愿者用于本研究人群，以消除背景抗逆转录病毒和其他治疗的混杂效应，并避免将HIV阳性患者置于可能导致对其他可用抗逆转录病毒药物产生耐药性的单药治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Tipranavir is a newly-marketed HIV protease inhibitor that must be administered with ritonavir. Many individual drug-drug interaction studies have demonstrated its high interaction potential. The results of some of these interaction studies (in particular, those with other protease inhibitors) were surprising, and not predicted on the basis for these interactions, and will allow for a general signal of potentially important drug interactions for further exploration. Healthy male and female volunteers are selected for this study population to remove the confounding effects of background antiretroviral and other therapies and to avoid placing HIV positive patients on monotherapy which may lead to the development of resistance to other available antriretroviral drugs.